| CD10 expression as a prognostic factor in female patients with invasive ductal carcinoma of the breast E Sadaka, W Almorsy, A Elsaka J Am Sci 12 (4), 71-7, 2016 | 10 | 2016 |
| Treatment outcome of gestational trophoblastic neoplasia A Maria, M El-Shebiney, E Sadaka, M Ramadan J Am Sci 8 (11), 261-7, 2012 | 5 | 2012 |
| Poor survival outcome of docetaxel every three weeks plus prednisone for treatment of patients with hormone-refractory metastatic prostate cancer S Mansour, M El Shebiney, NM Abd El Bary, E Sadaka, A Maria Hematology/Oncology and Stem Cell Therapy 3 (3), 121-127, 2010 | 4 | 2010 |
| Male breast cancer-a 10-year review of 29 cases at Tanta University Hospital H Shawky, SG Younes, E Sadaka, SED Elgohary, FA Sallam Life Sci J 10 (1), 2013 | 2 | 2013 |
| Impact of breath-hold technique on incidence of cardiac events in adjuvant left breast cancer irradiation AA Mahmoud, EA Sadaka, M Abouegylah, SA Amin, H Elmansy, MF Asal, ... Journal of Cancer Research and Clinical Oncology 149 (9), 5853-5859, 2023 | 1 | 2023 |
| Mammographic breast density as a predictive factor of local recurrence in female patients with invasive breast cancer E Sadaka, W Almorsy, A Albadry, AA Salama Cancer Biol 8, 97-101, 2018 | 1 | 2018 |
| Lymph node ratio as a prognostic factor in stage III colon cancer E Sadaka, A Maria, M El-Shebiney Journal of American Science 8 (9), 1137-41, 2012 | 1 | 2012 |
| A Clinical Phase II Study of Sorafenib in Advanced Hepatocellular Carcinoma HSG El Deen, EAE Sadaka Anaplastology 1 (101), 2161-1173.1000101, 2012 | 1 | 2012 |
| Prognostic Value Of Basal Markers (Epidermal Growth Factor Receptor" EGFR" And Cytokeratin 5/6) Expression In Triple-Negative Invasive Breast Cancer. AW ElFeky, EM Saied, H Shawky, E Sadaka JPMA. The Journal of the Pakistan Medical Association 73 (4), S161-S166, 2023 | | 2023 |
| THREE-WEEKLY DOCETAXEL WITH PREDNISOLONE FOR PATIENTS WITH HORMONE-REFRACTORY METASTATIC PROSTATE CANCER: PRELIMINARY RESULTS S Mansour, A Maria, E Sadaka, M El Shebiney, N Abd El Bary Kasr Al-Ainy Center of Clinical Oncology & Nuclear Medicine, 2017 | | 2017 |
| Metronomic Oral Cyclophosphamide Prednisolone Chemotherapy after Docetaxel failure in Metastatic Hormone-refractory Prostate Cancer W Almorsy, E Sadaka Journal of American Science 12 (9), 2016 | | 2016 |
| Body Mass Index (BMI) As a Prognostic Factor in Breast Cancer E Sadaka, S Galal Journal of American Science 3, 9, 2013 | | 2013 |
| Management of gastrointestinal stromal tumors: Five years period, Tanta experience M El-Shebiney, A Maria, E Sadaka, A El-Namer Life Science Journal 10 (1), 2013 | | 2013 |
| Role of Pregabaline in prevention of Oxaliplatine neuropathy. E Sadaka, A Maria Journal of American Science 9 (3), 2013 | | 2013 |
| Prognostic factors for supraclavicular relapse in N1 breast cancer patients. May that judge the need for supraclavicular irradiation? E Sadaka, A Maria, M El-Shebiney Journal of American Science 8 (10), 2012 | | 2012 |
| THREE-WEEKLY DOCETAXEL WITH PREDNISOLONE FOR PATIENTS WITH HORMONE-REFRACTORY METASTATIC PROSTATE CANCER: PRELIMINARY RESULTS AEH Abu-Hamar, S Mansour, M El Shebiney, N Abd El Bary, E Sadaka, ... Research in Oncology 5 (3-4), 31-37, 2009 | | 2009 |
| Impact of Breast Cancer Molecular Subtypes on the Incidence of Axillary lymph Nodes Metastases E Sadaka, W Almorsy | | |
| Comparison of Zoledronic Acid Every 12 Weeks versus Standard 4 Weeks Regimen in Breast Cancer Patients with Bone Involvement E Sadaka, R Khedr | | |
| Prognostic Impact of EGFR and CK5/6 as Basal-Markers in Triple-Negative breast Cancers RAEG Khedr, E Sadaka, K Gawis, SH El-Shorbagy | | |
| Poor survival outcome of docetaxel every three weeks plus prednisone for treatment of patients with hormone-refractory metastatic prostate cancer ES El Bary, A Maria | | |
